DeepMed Research

Ottawa Hospital Research Institute

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 2001-01-01

Employees: 5K

Market Cap: -

Website: http://www.ohri.ca

Clinical Trials

Bone Mineral Density (BMD) in Cemented Versus Cementless Hip Resurfacing

Not Applicable

Completed

Conditions: Osteoarthritis

Interventions: Device: Conserve
Device: Cormet

First Posted Date: 2011-05-13

Last Posted Date: 2018-04-02

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 120

Registration Number: NCT01353326

Locations: 🇨🇦
Ottawa General Hospital, Ottawa, Ontario, Canada

Evaluation of the Nursing C-Spine (Phase IV)

Phase 4

Completed

Conditions: Fracture of Cervical Spine
Fracture Dislocation of Cervical Spine

Interventions: Other: Clinical decision rule - clearing the c-spine

First Posted Date: 2011-05-13

Last Posted Date: 2011-05-13

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 3633

Registration Number: NCT01353352

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada

Qualitative and Quantitative HIV RNA Detection in Saliva Using the Oragene RNA Kit

Completed

Conditions: HIV Infections

First Posted Date: 2011-04-29

Last Posted Date: 2011-04-29

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 40

Registration Number: NCT01344642

Locations: 🇨🇦
The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada

Creating a Tissue Bank of Knee Capsules

Withdrawn

Conditions: Osteoarthritis
Knee Joint Contractures

First Posted Date: 2011-03-22

Last Posted Date: 2015-04-23

Lead Sponsor: Ottawa Hospital Research Institute

Registration Number: NCT01320124

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada

Kidney Transplant Failure

Terminated

Conditions: Acute Graft Rejection
Renal Failure Chronic Requiring Dialysis

First Posted Date: 2011-02-15

Last Posted Date: 2019-09-06

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 270

Registration Number: NCT01296061

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada

IXO+A in mCRC With Liver-only Metastases

Phase 2

Withdrawn

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab

First Posted Date: 2011-02-11

Last Posted Date: 2013-06-05

Lead Sponsor: Ottawa Hospital Research Institute

Registration Number: NCT01293942

Locations: 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦
McGill University Health Centre, Montreal, Quebec, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada

and more 1 locations

PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot

Phase 3

Completed

Conditions: Postpartum
Venous Thromboembolism

Interventions: Drug: Dalteparin Sodium

First Posted Date: 2011-01-11

Last Posted Date: 2017-08-01

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 62

Registration Number: NCT01274637

Locations: 🇺🇸
University of Virginia Medical Center, Charlottesville, Virginia, United States
🇺🇸
Puget Sound Blood Center, Seattle, Washington, United States
🇨🇦
McMaster University Medical Centre, Hamilton, Ontario, Canada

and more 4 locations

Weaning And Variability Evaluation

Completed

Conditions: Mechanically Ventilated Patients
Extubation

First Posted Date: 2010-11-10

Last Posted Date: 2017-07-07

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 660

Registration Number: NCT01237886

Locations: 🇺🇸
The University of Michigan Medical Center, Ann Arbor, Michigan, United States
🇺🇸
Columbia University, New York, New York, United States
🇺🇸
Intermountain Medical Center/University of Utah School of Medicine, Salt Lake City, Utah, United States

and more 11 locations

Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation

Phase 3

Completed

Conditions: Hematologic Malignancies

Interventions: Other: Red blood cell Transfusion

First Posted Date: 2010-11-09

Last Posted Date: 2016-10-12

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 300

Registration Number: NCT01237639

Locations: 🇨🇦
Hamilton Health Sciences Centre, Hamilton, Ontario, Canada
🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦
London Health Sciences Centre, University Hospital, London, Ontario, Canada

and more 1 locations

IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer

Phase 2

Conditions: Rectal Cancer

Interventions: Drug: IXO regimen

First Posted Date: 2010-11-09

Last Posted Date: 2012-10-15

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 15

Registration Number: NCT01237665

Locations: 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy